Trial reportThe New England journal of medicine2026
Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents.
Trial report in The New England journal of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04250116 (Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents (ADAPT AF-DES)
Who cites it
13 citing papers in PubMed.
- Oral anticoagulant monotherapy versus oral anticoagulant plus antiplatelet therapy in adults with stable coronary artery disease.The Cochrane database of systematic reviews · 2026Article
- Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.Journal of clinical medicine · 2026Review
- Advances in Clinical Cardiology 2025: A Summary of Key Clinical Trials.Advances in therapy · 2026Review
- Optimal antithrombotic therapy for patients with atrial fibrillation and prior stent.Journal of thoracic disease · 2026Article
- Risk and Timing of Intracerebral Hemorrhage Expansion Among Patients Treated with Antithrombotic Agents.Neurocritical care · 2026Article
- Korean Society of Interventional Cardiology Expert Consensus for the Management of Chronic Coronary Syndrome: Part 1.Korean circulation journal · 2026Review
- Antithrombotic Management in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation.Current cardiology reports · 2026Review
- Clopidogrel vs. Aspirin in Double Antithrombotic Therapy for Patients on Oral Anticoagulation Undergoing Coronary Stenting.Journal of cardiovascular development and disease · 2026Review
- Anticoagulation alone vs anticoagulation plus antiplatelet therapy in atrial fibrillation with stable coronary disease: A meta-analysis of randomized trials.Heart rhythm O2 · 2026Article
- Sex Differences in the Effect of Oral Anticoagulation Monotherapy for Atrial Fibrillation With Coronary Artery Disease.JACC. Asia · 2026Article
- Efficacy and safety of direct oral anticoagulants for intermediate stroke risk in patients with atrial fibrillation (SINGLE-AF): Study design and protocol.Heart rhythm O2 · 2026Article
- ADAPT AF-DES and the Limits of Non-inferiority in Long-term Antithrombotic Therapy.European cardiology · 2026Article
- Antithrombotic Management in Patients With Atrial Fibrillation Following Percutaneous Coronary Intervention: An Updated Clinical Review.Journal of arrhythmia · 2025Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
51 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite guideline recommendations, evidence for the use of non-vitamin K antagonist oral anticoagulant (NOAC) monotherapy in patients with atrial fibrillation after implantation of a drug-eluting stent remains limited.
methodsIn this multicenter, randomized, open-label, noninferiority trial in South Korea, we assigned patients with atrial fibrillation who had undergone the implantation of a drug-eluting stent at least 1 year earlier in a 1:1 ratio to receive NOAC monotherapy or combination therapy (NOAC plus clopidogrel). The primary end point was net adverse clinical events, a composite of death from any cause, myocardial infarction, stent thrombosis, stroke, systemic embolism, or major bleeding or clinically relevant nonmajor bleeding at 12 months. The noninferiority margin was 3.0 percentage points.
resultsA total of 960 patients underwent randomization: 482 patients to receive monotherapy and 478 to receive combination therapy. The mean age of the patients was 71.1 years, and 21.4% were women. At 12 months, a primary end-point event had occurred in 46 patients (Kaplan-Meier estimate, 9.6%) in the monotherapy group and in 82 patients (Kaplan-Meier estimate, 17.2%) in the combination-therapy group, for an absolute difference of -7.6 percentage points (95.2% confidence interval [CI], -11.9 to -3.3; P<0.001 for noninferiority) and a hazard ratio of 0.54 (95.2% CI, 0.37 to 0.77; P<0.001 for superiority). Major bleeding or clinically relevant nonmajor bleeding occurred in 25 patients (5.2%) in the monotherapy group and in 63 patients (13.2%) in the combination-therapy group (hazard ratio, 0.38; 95% CI, 0.24 to 0.60).
conclusionsAmong patients with atrial fibrillation who had undergone implantation of a drug-eluting stent at least 1 year earlier, NOAC monotherapy was noninferior to combination therapy for net adverse clinical events. (Funded by Cardiovascular Research Center and Samjin Pharmaceutical; ADAPT AF-DES ClinicalTrials.gov number, NCT04250116.).
Indexed as
Identifiers
41211917What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.